Novavax vaccine shows 93% efficacy against Covid variants

The The experimental covid-19 vaccine developed by Novavax Inc. has shown high efficacy against the coronavirus, including mutated variants, in a large-scale trial.

The vaccine had a 90% effective in preventing symptomatic cases of covid and 100% effective in preventing moderate and severe symptomsthe US biotech company reported on Monday. The vaccine was 93% effective against the variants of concern, he said.

Jorge Geffner: “The Delta variable could have some level of vaccine resistance”

The vaccine uses recombinant protein technology, also used in the experimental vaccine developed by Sanofi and GlaxoSmithKline Plc. At over 90%, the overall efficacy of the vaccine is close to the rates reported for the mRNA vaccines developed by Pfizer Inc.-BioNTech SE and Moderna Inc., and for the Sputnik V vaccine from Russia, which uses viral vector technology. . . However, immunologists tend to caution against comparing efficacy results in different trials because the conditions and methods of evaluation are not the same.

The phase 3 trial of Novavax included nearly 30,000 participants in the United States and Mexico and studied the efficacy of the vaccine against the major variants circulating in the United States., as defined by the Centers for Disease Control and Prevention. A single case of the highly contagious delta strain – which was first identified in India and remains rare in the United States – was detected among trial participants, so the vaccine’s efficacy against it was not detected. is inconclusive.

In results published in March of a trial involving 15,000 people in the UK, the vaccine was 90% effective in preventing symptoms of covid in all variants and the original version of the virus.

What do we know about the Indian and South African variants found in Argentina

The company had previously said it would not seek authorization for the vaccine in the United States and Europe until the third quarter of the year.. Novavax says it is on track to achieve a manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million per month by the end of 2021.

“Novavax takes one more step towards responding to the serious and persistent global need for COVID-19 vaccines,” pharmaceutical company CEO Stanley C. Erck said in a statement. “Novavax continues to work with a sense of urgency to complete our regulatory dossiers and deliver this vaccine, built on a well-understood and proven platform, to a world that is still in dire need of vaccines.”